Clinical trial
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
NCT05165485
Study timeline
Study start (actual)2022-01-07Date precision: day
Registry last updated2024-12-20
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Interventions
RevefenacinDRUG · verified · RxNorm: revefenacin
TiotropiumDRUG · verified · RxNorm: tiotropium
Sponsors & collaborators
Theravance Biopharmalead sponsor
Viatris Inc.collaborator
Mapped research locations
ClearwaterFlorida, United States3MiamiFlorida, United States2CincinnatiOhio, United States2ColumbusOhio, United States2SpartanburgSouth Carolina, United States2St LouisMissouri, United States1San AntonioTexas, United States1San DiegoCalifornia, United States1TampaFlorida, United States1PortlandOregon, United States1PhoenixArizona, United States1OrlandoFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05165485 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.